Satavaptan

Phase 3Small molecule

Sanofi

Satavaptan is one of 74 small molecule programs targeting Ascites. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AscitesActive, not recruiting

HyponatremiaActive, not recruiting

CirrhosisActive, not recruiting

AscitesPhase 2

Active, not recruiting

HyponatremiaPhase 3

Active, not recruiting

CirrhosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Satavaptan

Sanofi

Phase 3

3 2

Proamatine

Takeda

Preclinical

9 3

Crestor

AstraZeneca

Preclinical

2 4

HEPCLUDEX

Gilead

Preclinical

1 5

Thalomid

Bristol-Myers Squibb

Preclinical

1 6

Revia

Teva

Preclinical

1 7

Cipro

Bayer

Preclinical

1 8

Dobutrex

Eli Lilly

Preclinical

1 9

Azulfidine

Pfizer

Preclinical

1 10

Farxiga

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cirrhosis3 trials

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00359437·501 enrolled

Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)

Completed· Sanofi logo

Sanofi·Phase 3·NCT00358878·463 enrolled

Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00366795·241 enrolled

Ascites3 trials

Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites

Completed· Sanofi logo

Sanofi·Phase 2·NCT00501722·110 enrolled

Satavaptan Dose-Ranging Study in the Prevention of Ascites

Completed· Sanofi logo

Sanofi·Phase 2·NCT00501384·151 enrolled

Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites

Completed· Sanofi logo

Sanofi·Phase 2·NCT00501566·148 enrolled

Hyponatremia1 trial

A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00728091·2 enrolled

Efficacy1 trial

Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Completed· Sanofi logo

Sanofi·Phase 2·NCT00032734·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Satavaptan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Satavaptan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Satavaptan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Satavaptan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cirrhosis3 trials

Ascites3 trials

Hyponatremia1 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News